Follow
About Kevin
Kevin Huang is a senior equity research analyst and is primarily responsible for providing analytical coverage of several industries within health care, which includes biotechnology, medical devices, health care providers and services, and health care technology. His role involves keeping up-to-date with health care policy and regulation, industry trends, and technological advancements. Prior to joining CFRA in 2016, Mr. Huang worked at PricewaterhouseCoopers as a senior associate in Risk Assurance. He holds a BSBA in finance and accounting from the Olin Business School, Washington University in St. Louis, Missouri and is also a CFA Charterholder
Kevin's Articles
BioMarin Pharmaceutical (BMRN) is a biotechnology company with a strong track record of developing and commercializing therapies for serious and life-threatening rare diseases and medical conditions, suggests analyst Kevin Huang in CFRA Research's flagship newsletter The Outlook.
Kevin Huang
HEALTHCARE
Tickers: BMRN
Kevin Huang, an analyst with CFRA Research, highlights three stocks from the broad healthcare market that each recently earned upgrades to "strong buy" ratings. Here's his review from the CFRA's flagship weekly newsletter, The Outlook.
Kevin Huang
HEALTHCARE
Our latest focus stock is Stryker Corporation (SYK), a leading medical devices company which carries CFRA's highest recommendation of 5-STARS, or Strong Buy, explains Kevin Huang, a leading analyst with CFRA Research.
Kevin Huang
HEALTHCARE
Tickers: SYK